{"altmetric_id":854326,"counts":{"readers":{"mendeley":251,"citeulike":1,"connotea":0},"blogs":{"unique_users_count":1,"unique_users":[757],"posts_count":1},"total":{"posts_count":4},"twitter":{"unique_users_count":3,"unique_users":["DrADKline","sciencescanner","mkoeris"],"posts_count":3}},"selected_quotes":["Worth remembering post hoc analysis played a part in Ph2 for bapi: Key phase 2 was negative in pre-specified analysis"],"citation":{"abstract":"Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.","abstract_source":"pubmed","altmetric_jid":"4f6fa5ea3cf058f610005b59","authors":["S Salloway","R Sperling","S Gilman","N C. Fox","K Blennow","M Raskind","M Sabbagh","L S. Honig","R Doody","C H. van Dyck","R Mulnard","J Barakos","K M. Gregg","E Liu","I Lieberburg","D Schenk","R Black","M Grundman","For the Bapineuzumab 201 Clinical Trial Investigators"],"doi":"10.1212\/wnl.0b013e3181c67808","first_seen_on":"2012-07-24T15:24:39+00:00","issns":["0028-3878","1526-632X"],"issue":"24","journal":"Neurology","last_mentioned_on":1419176212,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2790221\/","http:\/\/www.neurology.org\/content\/73\/24\/2061","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19923550"],"pmid":"19923550","pubdate":"1970-01-01T01:00:00+00:00","publisher":"American Academy of Neurology","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"},{"name":"Neurosciences","scheme":"era"},{"name":"Cognitive Science","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"2061","subjects":["neurology"],"title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","type":"article","volume":"73","mendeley_url":"http:\/\/www.mendeley.com\/research\/phase-2-multiple-ascending-dose-trial-bapineuzumab-mild-moderate-alzheimer-disease"},"altmetric_score":{"score":11.492,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":11.492},"context_for_score":{"all":{"total_number_of_other_articles":4692005,"mean":5.4291783848369,"rank":362237,"this_scored_higher_than_pct":92,"this_scored_higher_than":4329771,"rank_type":"exact","sample_size":4692005,"percentile":92},"similar_age_3m":{"total_number_of_other_articles":76021,"mean":5.4367890028939,"rank":6349,"this_scored_higher_than_pct":91,"this_scored_higher_than":69672,"rank_type":"exact","sample_size":76021,"percentile":91},"this_journal":{"total_number_of_other_articles":6977,"mean":9.3207887041285,"rank":1101,"this_scored_higher_than_pct":84,"this_scored_higher_than":5876,"rank_type":"exact","sample_size":6977,"percentile":84},"similar_age_this_journal_3m":{"total_number_of_other_articles":34,"mean":4.5184242424242,"rank":3,"this_scored_higher_than_pct":91,"this_scored_higher_than":31,"rank_type":"exact","sample_size":34,"percentile":91}}},"demographics":{"poster_types":{"member_of_the_public":2,"science_communicator":1},"users":{"twitter":{"cohorts":{"Members of the public":2,"Science communicators (journalists, bloggers, editors)":1}},"mendeley":{"by_status":{"Unspecified":4,"Professor > Associate Professor":17,"Researcher":63,"Student  > Doctoral Student":12,"Student  > Ph. D. Student":44,"Student  > Postgraduate":15,"Student  > Master":26,"Other":19,"Student  > Bachelor":40,"Lecturer":1,"Lecturer > Senior Lecturer":1,"Professor":9},"by_discipline":{"Medicine and Dentistry":89,"Social Sciences":4,"Psychology":8,"Mathematics":1,"Unspecified":15,"Pharmacology, Toxicology and Pharmaceutical Science":6,"Arts and Humanities":1,"Engineering":7,"Chemistry":8,"Neuroscience":16,"Immunology and Microbiology":1,"Agricultural and Biological Sciences":81,"Computer Science":1,"Nursing and Health Professions":2,"Biochemistry, Genetics and Molecular Biology":10,"Veterinary Science and Veterinary Medicine":1}}},"geo":{"twitter":{"FR":1,"GB":1,"US":1},"mendeley":{"SG":1,"NL":1,"US":7,"CN":1,"EG":2,"GB":3,"FR":1,"DE":1,"RU":1,"ES":5,"IN":1}}},"posts":{"blogs":[{"title":"Bapineuzumab Does Not Work Against Alzheimer's","url":"http:\/\/pipeline.corante.com\/archives\/2012\/07\/24\/bapineuzumab_does_not_work_against_alzheimers.php?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+InThePipeline+%28In+the+Pipeline%29","citation_ids":[854325,854326],"posted_on":"2012-07-24T12:45:00+00:00","summary":"This long, long story may finally be coming to an end. Immune-based therapies against beta-amyloid (and the associated amyloid plaques) have been in development for many years now (an excellent review here), and Elan has been in the thick of it for most of","author":{"name":"In the Pipeline","url":":\/\/\/home\/corante\/public_html\/pipeline\/","description":""}}],"twitter":[{"url":"http:\/\/twitter.com\/DrADKline\/status\/435772618688315393","license":"public","citation_ids":[854326],"posted_on":"2014-02-18T13:47:43+00:00","author":{"name":"Dr. Adam D. Kline","url":"https:\/\/www.amazon.co.uk\/3000-Days-Dementia-Dr-Kline\/dp\/0955713072","image":"https:\/\/pbs.twimg.com\/profile_images\/824339115105808385\/HAJJlnzU_normal.jpg","description":"Spent almost a decade in #Alzheimer's R&D, filing several patent applications. The author of 3000 Days of Dementia. Views my own, not advice of any kind.","id_on_source":"DrADKline","tweeter_id":"1032288734","geo":{"lt":46,"ln":2,"country":"FR"},"followers":1058},"tweet_id":"435772618688315393"},{"url":"https:\/\/twitter.com\/sciencescanner\/status\/546648146886283265","license":"datasift","citation_ids":[854326],"posted_on":"2014-12-21T12:47:29+00:00","author":{"name":"David Grainger","url":"http:\/\/www.drugbaron.com","image":"https:\/\/pbs.twimg.com\/profile_images\/694415853891272705\/e6WgW03B_normal.jpg","description":"VC (Partner at Medicxi) & pharma R&D blogger as DrugBaron and on @Forbes. Passionate advocate of virtual. asset-centric drug discovery and development","id_on_source":"sciencescanner","tweeter_id":"71372467","geo":{"lt":52.2,"ln":0.11667,"country":"GB"},"followers":5196},"tweet_id":"546648146886283265"},{"url":"https:\/\/twitter.com\/mkoeris\/status\/546690774554120192","license":"datasift","rt":["sciencescanner"],"citation_ids":[854326],"posted_on":"2014-12-21T15:36:52+00:00","author":{"name":"Michael Koeris","url":"http:\/\/www.sample6.com","image":"https:\/\/pbs.twimg.com\/profile_images\/478272477672767490\/dICS0FFW_normal.jpeg","description":"Founder\/CEO @sample6tech, Founder\/BOD @biotechstart, BOD @addgene. Love biotech, VC\/PE, basketball & Boston. Proud husband of @daliejimenez & rookie father","id_on_source":"mkoeris","tweeter_id":"20468289","geo":{"lt":42.35843,"ln":-71.05977,"country":"US"},"followers":2123},"tweet_id":"546690774554120192"}]}}